Company Overview

Development Stage

  • Stage: IPO上市, 北交所。
  • Ranking: Ranked #17 in Neijiang by popularity
  • Honors: 民营科技企业 中华老字号 According to algorithm
  • Salary: 56.8% of positions earn 4.5-8K, In 2026 vs last yeargrew by 27%.。.
  • Recruiting: In 2026 vs 2025decreased by 56%.
  • Requirement: Education: 大专 leads with 56.7%. Experience: 1-3年 leads with 61.2%.
  • Region: Distributed across 2 regions, 内江: 53.7%, 赤峰: 9%, 成都: 6%, 宜昌: 4.5%.

About the Company

四川梓橦宫药业股份有限公司是以药品的研发、生产与营销为主的国家高新技术企业。“梓橦宫”品牌为“中华老字号”品牌,同时“梓橦宫”商标也是“中国驰名商标”。 梓橦宫药业旗下拥有1个子公司、2个生产基地。拥有95个药品生产批准文号,片剂、硬胶囊剂、散剂、搽剂、软膏剂等8个剂型、2种原料药、32种中药饮片炮制。梓橦宫药业已上市的新药品种主要有:胞磷胆碱钠片、苯甲酸利扎曲普坦胶囊、东方胃药胶囊等。同时,控股子公司昆明梓橦宫还拥有全国独家民族药品种清肠通便胶囊、玄驹胶囊、虎杖伤痛酊以及40多个在云南省具有竞争优势的基药品种和低价普药品种。 多年来,梓橦宫药业以企业技术中心为新药研发中心,努力提高自身科研能力,先后研发了胞磷胆碱钠片、苯甲酸利扎曲普坦胶囊等多个新药品种。同时公司积极与多家高等院校、科研院所合作,建立新药创新研发平台。公司现已获得新药证书4个、发明专利8个、实用新型专利1个、外观专利10个、注册商标15个。梓橦宫药业已上市的新药品种主要有:胞磷胆碱钠片(欣可来)、苯甲酸利扎曲普坦胶囊(欣渠)、东方胃药胶囊、清肠通便胶囊、玄驹胶囊、咳痰合剂、虎杖伤痛酊。 梓橦宫药业不断改革创新,开拓进取, 现有员工人数286人。其中博士1人,硕士8人,本科34人。具有专业职称64人,其中高级职称20人,中级职称15人,初级职称29人,专业技术人员占员工总数的27%。公司在成都设立了营销中心,营销网络遍布全国。 公司致力于“新特药”开发事业,以打造高性价比一线专科用药的研发和营销为核心竞争力,将技术革新与创新,产、学、研合作,自主研发与技术引进相结合,力求实现“生产一代,储备一代,研发一代”,代代相扣,层层推进。在研新药产品主要有口服抗2型糖尿病化学药三类新药维格列汀原料及片剂、治疗各种疼痛的化学药三类新药塞来昔布胶囊等。公司重视团队能力提升,率先引入目前世界先进的战略绩效管理体系——平衡计分卡,实施全面战略绩效管理。梓橦宫药业正以人才、科研和营销的优势,迅速形成以研发、生产、营销为主的高科技现代制药企业。

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

梓橦宫 Financing History (1 rounds)

Manage
IPO上市
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Market: 北交所
  • Deal: 北交所

梓橦宫 How Fast Is Hiring Growing? (9 open positions)

Manage
Note: How fast is hiring at 四川梓橦宫药业股份有限公司 growing? 梓橦宫2026: 39 openings (down 56%), 2025: 89 openings (up 112%), 2024: 42 openings (up 110%), 2023: 20 openings (down 17%), 2022: 24 openings (up 700%), 2021: 3 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

梓橦宫 Master's Degree Job Demand Analysis

(More)
N/A
Growth Rate
梓橦宫 Master's Hiring by Year: 2023 — same as 2022
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at 四川梓橦宫药业股份有限公司 growing? 梓橦宫Master's recruitment over the years: 2023: 2 openings (down 17%), 2022: 2 openings (up 700%).

梓橦宫 — What Are the Salaries Like? (67 records)

Manage
梓橦宫 Salary Overview
salary range: 3K - 20K, 56.8% of roles pay ¥4.5-8K
Note: salary statistics are based on 67 salary records from the past year and depend on the job sample. For reference only.
How is the salary at 四川梓橦宫药业股份有限公司?梓橦宫56.8% of positions earn 4.5-8K, Undergraduate salary: ¥。Neijiang salary ranking top 50,销售类 average salary ¥8.3K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of 梓橦宫

(More)
Are salaries high at 四川梓橦宫药业股份有限公司? We provide: 医药代表,销售,qc,信息,组长,工艺员,质检,车间,qa,主操,人力资源副经理,分销经理,品牌,技术部,推广,生产技术,otc代表,人才发展,会计,公用系统技术员. Click to view detailed salary analysis by job.

梓橦宫 honors, qualifications & industry associations

梓橦宫 Related Industry Tags

Tags are auto-annotated by keyword text matching and may be correlated. For reference only.

Job Category

  • 销售类
    41.8% of total 41.8%
  • 工厂生产类
    26.9% of total 26.9%
  • 经营管理类
    16.4% of total 16.4%
  • 质量管理类
    13.4% of total 13.4%

Education

  • 大专
    56.7% of total 56.7%
  • 本科
    31.3% of total 31.3%
  • 不限
    10.4% of total 10.4%
  • 高中
    1.5% of total 1.5%

Experience

  • 1-3年
    61.2% of total 61.2%
  • 3-5年
    14.9% of total 14.9%
  • 5-10年
    13.4% of total 13.4%
  • 不限
    10.4% of total 10.4%
View Detailed Analysis

What does 四川梓橦宫药业股份有限公司 require? Who is 梓橦宫 hiring? 梓橦宫 recruitment: 销售类占比最多占41.8%,其次是工厂生产类占26.9%. What education can get in at 梓橦宫? 大专占比最多占56.7%,其次是本科占31.3%. Work experience required at 梓橦宫? 1-3年占比最多占61.2%,其次是3-5年占14.9%. Where are the job locations at 梓橦宫? 内江占比最多占53.7%,其次是赤峰占9%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 14,546.338万(元)
Legal Representative: 唐铣
Date Established:
Credit Code: 91511000756614555R
Registered Address: 内江市经济技术开发区安吉街456号

Partners & Suppliers

供应苯甲酸利扎曲普坦原料药,用于公司偏头痛产品生产 Source
供应商 其他原料药
梓橦宫药品经销商,前五大客户之一 Source
合作客户 医药商业(经销商)
梓橦宫药品经销商,前五大客户之一 Source
合作客户 医药商业(经销商)
梓橦宫药品经销商,前五大客户之一 Source
合作客户 医药商业(经销商)
梓橦宫药品经销商,多年位列前五大客户 Source
合作客户 医药商业(经销商)

People who follow 梓橦宫 also follow

梓橦宫 Competitors (Similar Companies)

“Dedicated to the R&D, production, and sales of high-end anti-tumor dru”
生命科学 生物信息 生物制药 干细胞
氨基酸 制药/药业 生化制品 生物科技/生物工程
生物制剂 生化药品 生物制品 抗生素
系统集成 仪器/仪表 建筑智能化 网络优化
功能材料 生产 轨道交通 智能制造/生产/加工
物业 建筑 社区管理 现代服务业
小家电 电器 烤面包机 创意设计
“Integrated Internet Marketing Services”
造纸/造纸厂/纸业 食品包装 微涂纸 印刷/包装
制冷 单向阀 制冷配件 生产
电脑配件/电脑外设 恒力弹簧 制造 配件
工业互联网 数字经济 大安全 网络通信
陶瓷 生产 抛光
“Only to improve your quality of life”

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates